

# Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma

Louise Bouard,<sup>1</sup> Benoit Tessoulin,<sup>2</sup> Catherine Thieblemont,<sup>3</sup> Kamal Bouabdallah,<sup>4</sup> Thomas Gastinne,<sup>1</sup> Lucie Oberic,<sup>5</sup> Sylvain Carras,<sup>6</sup> Caroline Delette,<sup>7</sup> Olivier Casasnovas,<sup>8</sup> Caroline Dartigeas,<sup>9</sup> Victoria Cacheux,<sup>10</sup> Sibylle Masse,<sup>11</sup> Olivier Hermine<sup>12</sup> and Steven Le Gouill<sup>2,13</sup>

<sup>1</sup>Department of Hematology, CHU Nantes, Nantes; <sup>2</sup>Department of Hematology CHU Nantes, INSERM CRCINA Nantes-Angers, and NeXT, Nantes University, Nantes; <sup>3</sup>Department of Hematology, Saint-Louis Hospital, AP-HP, Paris 7 University, Paris; <sup>4</sup>Department of Hematology, CHU Bordeaux, Bordeaux; <sup>5</sup>Department of Hematology, IUC Toulouse Oncopole, Toulouse; <sup>6</sup>Department of Hematology, CHU Grenoble, Grenoble; <sup>7</sup>Department of Hematology, CHU Amiens, Amiens; <sup>8</sup>Department of Hematology, CHU Dijon Bourgogne, INSERM 1231, Dijon; <sup>9</sup>Department of Hematology, CHU Tours, Tours; <sup>10</sup>Department of Hematology, CHU Clermont-Ferrand, Clermont-Ferrand; <sup>11</sup>Lysarc Institut Carnot CALYM, Lyon-Sud Hospital, Lyon; <sup>12</sup>Necker University Hospital, Paris and <sup>13</sup>Institut Curie, Paris France.

**Correspondence:** S. Le Gouill  
[steven.legouill@curie.fr](mailto:steven.legouill@curie.fr)

**Received:** July 8, 2021.

**Accepted:** February 10, 2022.

**Prepublished:** February 17, 2022.

<https://doi.org/10.3324/haematol.2021.279561>

©2022 Ferrata Storti Foundation

Published under a CC BY-NC license




## Appendix

**Supplemental Table 1.** Patients' characteristics

	OBSERVATION N=120		RITUXIMAB N=120	
<b>Gender (M/F)</b>	97/23		92/28	
<b>Median age-year (range)</b>	56 (29-65)		58 (27-65)	
<b>MIPI-nb (%) (low/int/high)</b>	63 (52.5) 31 (25.8) 26 (21.7)		70 (58.3) 34 (28.3) 16 (13.3)	
<b>Bone marrow involvement-nb (%)</b>	73 (60.8)		76 (64.4)	
<b>Mean CD34 nb (.10<sup>6</sup>/kg) (SD)</b>	7.84 (4.758)		8.00 (4.527)	
<b>Median time from ASCT to randomization (months)</b>	2.10		2.10	
<b>Events for EFS at stopping date</b>				
Progression	37	(30.8%)	16	(13.3%)
Death without event	6	(5.0%)	4	(3.3%)
Severe infection	4	(3.3%)	4	(3.3%)
Life threatening allergy to rituximab	0	(0.0%)	1	(0.8%)
<b>Events for PFS at stopping date</b>				
Progression	37	(30.8%)	16	(13.3%)
Death without progression	6	(5.0%)	4	(3.3%)
<b>Events for OS at stopping date</b>				
Death	24	(20.0%)	13	(10.8%)

**Supplemental Figure 1.** Flow-chart

*EOT: End of treatment; PD : progressive disease*



**Supplemental Table 2.** Number of patients with available data for biological parameters on the four different periods of follow-up

Periods Number of patients	Observation				Rituximab			
	1 N=120	2 N=120	3 N=116	4 N=107	1 N=120	2 N=119	3 N=104	4 N=99
<b>Neutropenia</b> Available data Missing data reason	109 11 Missing =11	99 21 EOT=3 Missing=18	82 34 EOT=8 Missing=26	74 33 EOT=15 Missing=18	106 14 EOT=1 Missing= 13	101 18 EOT=15 Missing= 3	97 7 EOT=5 Missing=2	94 5 EOT=1 Missing=4
<b>Ig Levels</b> Available data Missing data reason	70 50 Missing=50	74 47 EOT=3 Missing=44	70 46 EOT=8 Missing=38	58 49 EOT=15 Missing=34	62 58 EOT=1 Missing=57	67 52 EOT=15 Missing=37	73 31 EOT=5 Missing=26	77 22 EOT=1 Missing=21
<b>CD4 lymphopenia</b> Available data Missing data reason	66 54 Missing=54	60 60 EOT=3 Missing=57	41 75 EOT=8 Missing=67	37 70 EOT=15 Missing=55	46 74 EOT= 1 Missing= 73	66 53 EOT=15 Missing=38	50 64 EOT=5 Missing=59	40 59 EOT=1 Missing= 58

*EOT: End of treatment*